Study of XL999 in Adults With Solid Tumors
The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.
Cancer
DRUG: XL999
To determine the maximum tolerated dose (MTD) and to assess the safety and tolerability of XL999 administered as a single 4-hour intravenous (IV) infusion in subjects with solid tumors, Inclusion until 30 days post last treatment
To evaluate plasma pharmacokinetics (PK) and estimate renal elimination of XL999 administered as a single 4-hour IV infusion in subjects with solid tumors, Various timepoints from pre-dosing until 48 hours post dose.|To evaluate the PK of XL999 administered at a fixed weekly dose of 200 mg., At various timepoints from pre-dosing until 48 hours post dosing
The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.